ArticleFrontiers in cell and developmental biology2026
Establishing a novel mouse model of tacrolimus-induced post-transplant hepatocellular carcinoma pulmonary recurrence for transplant oncology.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term immunosuppression following transplantation places recipients at a high risk of malignancy. Hepatocellular carcinoma (HCC) recurrence after transplantation poses significant challenges to long-term survival of recipients. Several studies in transplant oncology have established cancer-transplant models to support the development of therapies for reducing the risk of post-transplant cancer recurrence. However, existing models fail to recapitulate the complex immune status of recipients and the authentic tumor microenvironment after transplantation. Methods: C57BL/6 recipient mice were injected intravenously with luciferase-expressing Hepa1-6 cells 7 days before receiving Balb/c cardiac allografts, followed by post-transplant immunosuppression with tacrolimus. On day 7 post-transplantation, the immune state of recipients was assessed by measuring serum inflammatory cytokines, and allograft rejection was evaluated by hematoxylin-eosin staining. Cancer progression was evaluated using Results: Allogeneic cardiac transplantation resulted in a significant increase in serum levels of pro-inflammatory cytokines accompanied by a marked reduction in cancer burden. Marked lymphocytic infiltration, hemorrhage, and structural disintegration were observed in the grafts of untreated animals. In contrast, tacrolimus treatment effectively attenuated both the inflammatory cytokine response and acute allograft rejection but, conversely, resulted in a significant increase in tumor burden. Histological analysis confirmed that malignancies were exclusively localized to the lungs, mirroring the most common site of clinical HCC recurrence post-transplantation. Conclusion: This model effectively simulates the elevated risk of cancer recurrence under post-transplant immunosuppression and faithfully recapitulates lung metastasis of HCC mediated by circulating cancer cells-the most common site of clinical recurrence following liver transplantation for HCC. It thus provides a reliable tool for basic research aimed at reducing risk of post-transplant cancer recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.